Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 119, Issue 12, Pages 3797-3806Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI37976
Keywords
-
Categories
Funding
- NIH [R01 AR45653]
- Muscular Dystrophy Association
- American Heart Association
- American Heart Association Scientisr Development
- NIH
- W.M. Keck Foundation
- NIH/National Heart, Lung and Blood Institute [HL089598-01, R01HL091947]
- Muscular Dystrophy Association [69238]
- Hankamer Foundation
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL091947, R01HL045565, R01HL089598] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045653, F32AR052630] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Cardiac complications are a common cause of death in individuals with the inherited multisystemic disease myotonic dystrophy type 1 (DM1). A characteristic molecular feature of DM1 is misregulated alternative splicing due to disrupted functioning of the splicing regulators muscleblind-like I (MBNL1) and CUG-binding protein 1 (CUGBP1). CUGBP1 is upregulated in DM1 due to PKC pathway activation and subsequent CUGBP1 protein hyperphosphorylation and stabilization. Here, we blocked PKC activity in a heart-specific DM1 mouse model to determine its pathogenic role in DM1. Animals given PKC inhibitors exhibited substantially increased survival that correlated with reduced phosphorylation and decreased steady-state levels of CUGBP1. Functional studies demonstrated that PKC inhibition ameliorated the cardiac conduction defects and contraction abnormalities found in this mouse model. The inhibitor also reduced misregulation of splicing events regulated by CUGBP1 but not those regulated by MBNL1, suggesting distinct roles for these proteins in DM1 cardiac pathogenesis. The PKC inhibitor did not reduce mortality in transgenic mice with heart-specific CUGBP1 upregulation, indicating that PKC inhibition did not have a general protective effect on PKC-independent CUGBP1 increase. Our results suggest that pharmacological blockade of PKC activity mitigates the DM1 cardiac phenotype and provide strong evidence for a role for the PKC pathway in DM1 pathogenesis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available